Changes in Taste Perception, Eating Habits, and Other Behavioral Aspects Associated With the Use of GLP-1 Receptor Agonists in Patients Undergoing Weight Loss Treatment: A Retrospective Observational Study

What this Trial Is About

This research investigates how GLP-1 receptor agonists, such as semaglutide or tirzepatide, affect taste perception, eating habits, and other behaviors in adults aged 18 to 60 undergoing weight loss treatment. The study is observational and retrospective, focusing on participants treated at specialized nutrition centers in Italy during 2025-2026. It aims to understand changes in food preferences and taste perception related to these treatments. The study collects data retrospectively from clinical records, dietary questionnaires, bioimpedance analysis for body composition, and metabolic assessments before and after at least 12 weeks of GLP-1 receptor agonist treatment. No new treatments are given as part of the study, and all data are anonymized following ethical and data protection guidelines. Researchers will analyze changes in body weight, body composition, gastrointestinal side effects, physical activity, and treatment adherence. Participants' involvement includes providing access to their past clinical and dietary records for at least 12 weeks of treatment with GLP-1 agonists. Researchers will measure changes in taste perception and food preferences as the primary outcome, along with secondary outcomes such as body weight changes and gastrointestinal side effects. The study adheres to ethical standards and protects participant privacy, with no extra costs or interventions beyond routine care.

Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients